

### 1. Patient personal details

Insurance number:	Institute:
Nama	Doctor code
Name:	
Date of birth:	Blood sample code:
	Date of blood sampling:
Place of birth:	
Address:	
Telephone number:	

**Gender:** female / male

**Race:** Asian /Indian / White / Black / Hispanic /N.A. (not applicable)

Date of interview: .....



# 2. Typisation:

1. Type 1 Diabetes	A, Immunological; special form: LADA?
	B, Idiopathic
2. Type 2 Diabetes	
1. Type 1 Diabetes   2. Type 2 Diabetes   3. Other types of diabetes	A, Infinitulological, special form: LADA? B, Idiopathic A, Genetic &-cell defection: - MODY 1 - MODY 2 - MODY 3 - MODY 5 B, Genetic defect of the insulin effect C, Endocrinopathy: - Acromegaly - Cushing-disease - Pheochromocytome - Hyperthyreosis - Somatostatinome - Glucagonome - Aldosteronome - Other: D, Medication induced: - thiazids - hormonal anticonception therapy - betaadrenergic therapy - steroids - thyroid hormones E, Infection: - congenital rubella infection - CMV infection G, Rare immunological forms, e.g.: - Anti-Insulin-Receptor-Antibody H, Genetic syndromes with diabetes: - Down-syndrome - Klinefelter-syndrome - Turner-syndrome
4. Gestational diabetes	
5. Impaired glucose	
tolerance IGT)	
6. Impaired fasting glucose (IFG)	
7. Non-diabetic	



# 3 Details from the medical history

S. Del					
AICONO	f vos: frogu	<u>//1.</u> opcy: N/A / occ	yes / 110	athly/wookly/daily	
	n yes. nequ	ency. N/A/ Occ	asionaliy/110 n)•	itiliy/weekiy/ualiy	
	for be	mit (per occasion		•••••	
-	Total alcohol	l concumption i			
		consumption i	in the last 2 w	eeks	
	If not: Did ye	ou drink alcoho	l earlier?	yes/no/ N//	A
	If yes:	frequency:	N/A / occasi	onally/monthly/we	ekly/daily
		amount (g/oc	casion):		
		for how many	vyears?		
		How long ago	did you stop	drinking alcohol?	
	Guide for est	imation of the c	amount:		
	1 dl beer (4.5	5 vol. %) = ~3.5 g	g alcohol		
	1 dl wine (12	.5 vol. %) = ~10	g alcohol		
	1 dl hard drir	1k (50 vol. %) = '	~40 g alcohol		
Smokin	g:	ves / no			
	if ves: amou	int (cigarettes/c	lav):		
	, for ho	ow many years?	· · · · · · · · · · · · · · · · · · ·		
		, ,			
i	if not: Di	d you smoke ea	rlier?	yes/no/ N/A	
	if yes	: amount (cigai	rettes/day):		••
		for how many	vyears?		
		How long ago	did you stop	smoking?	
Sport: 1	Type? Regula	rity?			
Drug at	ouse: yes/	no Prescribe	d medication	should not be inclu	ided here.
i	if yes: type o	of drug:		amount:	
	for ho	ow many years:			
<u>Known</u>	diseases:	yes / no			
	if yes	: please fill the	list		
1.	Liver disease	; since when? \	What type?		
2.	Autoimmun	e disease? Since	e when? Wha	it type?	
3.	Endocrine di	sease? Since w	hen? What ty	/pe?	
4.	Heart failure	? Since when?	What type?	F?	
5.	Arrhythmia?	' Since when? V	Vhat type?		
6.	Hypertensio	n? Since when?			
7.	Hyperlipidae	emia? Since whe	en?		
8.	<b>Obesity?</b> Sin	ce when?			
9.	Tumor? Sinc	e when? What	type?		
10.	Other releva	nt disease? Sin	ce when? W	nat type?	
11.	Syncope? W	hen? Reason? [	Duration?		
12.	Collapse? W	hen? Reason?			
13.	Complicatio	ns by pregnancy	y?		



# 4. Complications:

1 Macroangionathy:	Type/Stadium		Latest control
1 Coronary hoart			hy specialist
1. Coronary nearc		who	by specialise
disease		wile ~2	
2. Peripheral		nr	
artery disease			
3. Cerebral			
arteriosclerosis			
or ischemic			
stroke			
2. Microangiopathy:		Sinc	Latest control
	1. Stadium I-V.	е	by specialist
1. Diabetic	CKD Stage eGFR (ml/min/1,73 m <sup>2</sup> )	whe	- / -
nephiopathy	1. ≥90	n?	
	2. 60-89		
	3a. 45-59		
	3b. 30-44		
	4. 15-29		
	5. <15		
		<i>c</i> :	
	Albumin excretion	Sinc	
	Microalbuminuria	e.	
	Macroalbuminuria	whe	
	Macroalbummuna		
	2 A Non proliferative retinenative	Sinc	
2. Diabetic	2. A, Non-promerative retinopathy	е	Latest control
retinopathy	B, Promerative retinopathy	whe	by specialist?
. ,	C, Diabetic maculopathy	n?	
3. Diabetic	1. Peripheral sensomotoric polyneuropathy	Sinc	Latest control
neuropathy	2. Rare forms of the diabetic	e	by specialist?
	polyneuropathy:	whe	
	-Peripheral N. facialis paresis		
	-Diabetic Radiculopathy		
	3. Autonomic diabetic neuropathy (ADN):		
	-Cardiovascular ADN:		
	A, Pathological Ewina-tests:		Ewing-test
	1, Heart rate variation to deep breathing		scoring:
	2, Heart rate response to Valsalva manoeuvre		0 (normal),
	3, Heart rate response to standing (30:15 ratio)		1 (borderline) 2
	4, Blood pressure response to standing (orthostatic		(abnormal)
	hypotension)		
	5, Blood pressure response to a sustained handgrip		



					1			
	В,	B, Tachycardia at rest (Vagus defect)						
	С,	C, Non-Dipper circadian blood pressure						
	D,	D, Cardiac sympathetic denervation						
	C	actraintact	inal ADNI					
	- <u>G</u>	<u>Astrointest</u> Oeconhaai	<u>inai ADN:</u> 	licardar				
	A, R	Gastronard	is mounty u	ISUIUEI				
	<i>В,</i> С	Intectinal L	SIS NDN with dia	arrhoea/Oho	tination			
	С, П	Anorectal i	dysfunction	lincontinen	~v)			
	υ,	Anorectur	aysjunction	(meontinem	-			
	-A	DN of the u	rogenital sv	vstem				
	Α,	Urinary blo	ndder atony					
	В,	Erectile dys	, sfunction					
		-	-					
	- <u>A</u>	DN of the i	neuroendoc	rine system				
	Α,	Defect of t	he glucose c	counter regu	latory			
	res	sponses to	hypoglycaeı	mia				
							Neuropad-	
	-ADN of the thermoregulation					test:		
	Α,	A, Reduce of the perspiration						
	В,	B, Vasodilatation						
4. Diabetic foot	VVä	agner-Arms	strong class	lfication:	III			
syndrome		Areas of pressure	Superficial ulcer not	Deen ulcer including				
	A	which are sometimes called pre-ulcerative	including tendon, capsule or bone	tendon, capsule but not bone	Deep ulcer including bone and articulation			
		ICalon						
	в	B Infection Infection Infection						
		C Isthemia Isthemia Isthemia Isthemia						
		c Ischemia Ischemia Ischemia Ischemia						
	D	Infection & Ischemia	Infection & Ischemia	Infection & Ischemia	Infection & Ischemia			
3 Diabetic							Since when?	
cardiomyonathy								
4 Eatty liver disease							Since when?	
4. Fally liver disease		ort value fe	or hypoglycy	mia			When?	
э.пуродусета,	<7	n ma/di /<	3 9 mmol/l	) nlasma			How often?	
coma diabeticum	/	sourcentration					now orten:	
	Severe hypoglycemia:						When?	
	Requires assistance of another person to						How often?	
	act	tively admi	nister carbo	hydrates, gl	ucagon, or		(number per	
	tał	ke other co	rrective acti	ions			week/month/	
	Pla	asma gluco:	se concentra	ations may i	not be		year)	
	ava	ailable duri	ing an event	Ī				
	1			č				



6.Hypoglycemic	Neurological recovery following plasma glucose levels returning to normal considered sufficient evidence that event was induced by low plasma glucose concentration <b>Documented symptomatic hypoglycemia</b> Typical hypoglycemia symptoms accompanied by measured plasma glucose ≤70 mg/dL (≤3.9 mmol/L) <b>Asymptomatic hypoglycemia</b> Not accompanied by typical hypoglycemia symptoms but with measured plasma glucose ≤70 mg/dL (≤3.9 mmol/L) <b>Probable symptomatic hypoglycemia</b> Typical hypoglycemia symptoms not accompanied by plasma glucose determination but likely caused by plasma glucose ≤70 mg/dL (≤3.9 mmol/L) <b>Pseudo-hypoglycemia</b> Reports of typical hypoglycemia symptoms with measured plasma glucose >70 mg/dL (>3.9 mmol/L) but approaching that threshold	When? How often? (number per week/month/ year) When? How often? (number per week/month/ year) When? How often? (number per week/month/ year) When? How often? (number per week/month/ year) When?
shock		

#### 5. Medications taken regularly: yes/no

Please specify the name of the active substance (e.g. "acetylsalicylic acid"). Please specify the amount using the International System of Units –SI (e.g. milligram, gram)

if yes: details

Name of medication:...... active substance:...... dose: ....... dose without unit (number only!) unit: g / mg / IU if fluid, concentration (e.g. 10%, 1g/2ml, etc.)..... how many times per day (e.g. 3): ..... Method of administration: N/A / intravenious / oral / enteral / subcutan other notes: .....

Name of medication:.....active substance:....



dose: ..... dose without unit (number only!) unit: g / mg / IU if fluid, concentration (e.g. 10%, 1g/2ml, etc.)..... how many times per day (e.g. 3): ..... Method of administration: N/A / intravenious / oral / enteral / subcutan other notes: .....

Name of medication:...... active substance:..... dose: ...... dose without unit (number only!) unit: g / mg / IU if fluid, concentration (e.g. 10%, 1g/2ml, etc.)..... how many times per day (e.g. 3): ..... Method of administration: N/A / intravenious / oral / enteral / subcutan other notes: .....

Diet: yes / no; when yes, please describe. (X gr carbohydrates per day diet) 150 gr CH 165 gr CH 175 gr CH 200 mg CH 225 gr CH 250 gr CH

Medication allergy? Active substance? Since when? What happens?

#### 6. Admission details and state

Blood pressure: /	Hgmm	Heart rate:/mir		
Body weight:	kg	Body height:	cm	
Waist measurement:	cm	Hip measurement:	cm	
Waist-hip ratio:				



# 7. Laboratory parameters on admission

Date:

	Amylase (U/I)	
	Lipase (U/I)	
	White blood cell (WBC) count (G/l)	
	Red blood cell (RBC) count (T/l)	
	Haemoglobin (g/l) Conversion: mmol/I	
	Haematocrit (%)	
	MCV (fl)	
	MCHC (g/L)	
	Thrombocyte (G/I)	
	Glucose (mmol/l) Conversion: mg/dL	
	Blood urea nitrogen (mmol/l) Conversion: mg/dL	
	Creatinine (umol/l) Conversion: mg/dL	
	eGFR (CKD-EPI)	
	Uric acid (µmol/L)	
	Serum insulin pmol/l. (mU/l)	
	C-reactive protein (mg/l)	
	Lactate dehydrogenase LDH (U/I)	
	Calcium (mmol/l)	
	Phosphate (mmol/l)	
	Sodium (mmol/l)	
	Potassium (mmol/l)	
	Magnesium (mmol/l)	
	Total protein (g/l)	
	Albumin (g/l)	
	Cholesterol (mmol/l) Conversion: mg/dL	
	Triglyceride (mmol/l) Conversion: mg/dL	
	HDL-cholesterol	
	LDL-cholesterol	
	ASAT/GOT (U/I)	
	ALAT/GPT (U/I)	
	Gamma GT (U/I)	
	Total bilirubin (umol/l) Conversion: mg/dL	
	Direct/Conjugated bilirubin (umol/l) Conversion: mg/dL	
	Alkaline phosphatase (U/I)	
	Creatinine kinase (U/I)	
	Erythrocyte sedimentation rate(ESR)/Westergren (mm/h)	
	HbA1c%	
	Fructose amine (µmol)	
	C-peptide (ng/ml)	
	TSH (mIU/)	
	fT3 (mIU/)	
ļ	fT4 (mIU/)	
	IgA (g/l)	
ļ	IgM (g/l)	
	IgG (g/l)	



IgG4 (g/l)	
anti-GAD	
ICA	
IA-2-Antibody	
IGF-1	
Cortisol	
urine total protein	
urine albumin	
urine creatinine	
urine nitrite	
urine pH	
urine protein	
urine glucose	
urine ketone body	
urine urobilinogen	
urine bilirubin	
urine white blood cell	
urine red blood cell	
urine sediment test	
Other	

# 8. Genetic testing

Has it been performed earlier? yes / no If yes: please describe:.....

Genes	N/A	Pos	Neg	Results
MODY 1				
MODY 2				
MODY 3				
MODY 5				
HLA-Type				

# 9. File Uploading



### 10. Registered data:

### 1. ECG-parameters

1. QT interval (ms)	
2.QTc interval using Bazett's	
formula (QTc = QT/VRR) (ms)	
3.QTc interval using Fridericia	
formula (QTc = QT/[RR/1,000]1/3)	
(ms)	
4.QTc formula Framingham (QTc =	
QT + [0.154 × {1,000 – RR}]) (ms)	
5.QTc Hodges formulas (QTc = QT +	
1.75 × [60,000/RR – 60]) (ms)	
6. QTd (QT dispersion) (ms)	
7.PQ intrerval (ms)	
8.QRS interval (ms)	
9.RR interval (ms)	
10. STVQT: the duration of terminal	
part of T waves (Tpeak – Tend) and	
the short-term variability of QT	
interval (ms)	
11. Tpeak – Tend (ms)	
12.T wave amplitude (μV)	
13. STVRR (ms)	
14.Long-term QT interval variability	
15.Normalized QT interval variance	
16.QT variability index	
17. Variability ratio	



#### 1. Heart frequency variability

#### A, Time domain analysis

1.Tart1	
2.Tart2	
3.Domain	
4.Beats	
5.HRmax (bpm)	
6.HRmin (bpm)	
7.HRmean (bpm)	
8.RRmax (ms)	
9.RRmin (ms)	
10.RRmean (ms)	
11.SDRR (ms)	
12.pRR50 (%)	
13.rMSSD (ms)	
14.HRVi	
15.SD1	
16.SD2	
17.SD1/SD2	
18.S	
19.CVRR (%)	

### B, Frequency domain analysis

1. Tart1	
2. Tart2	
3. Domain	
4. Total (ms2)	
5. VLF (ms2)	
6. LF (ms2)	
7. VLF (%)	
8. LF (%)	
9. HF (%)	
10.LF/HF	

C, RR Tachogram (picture file uploading)

D, Histogram (picture file uploading)



#### 2. Assessment of AN with five standard cardiovascular reflex tests (CRT)

Test	Result	Normal value	Evaluation
Heart rate response to		≥15/min.	
deep breathing			
Valsalva ratio		≥1.21	
30/15 ratio		≥1.04	
Orthostatic systolic BP		≤10 mm Hg	
fall			
Diastolic BP elevation at		≥16 mm Hg	
handgrip			

CRT was scored as 0 (normal), 1 (borderline) or 2 (abnormal) and by this method an autonomic score (0-10) is calculated to express the overall severity of AN.